Profil
Dr. Jordi Mata-Fink is a Chief Executive Officer at Gate Bioscience, Inc.
Dr. Mata-Fink was previously employed as a Founder by Cygnal Therapeutics, Inc., a Director of Research by Rubius Therapeutics, Inc., and a Principal by Flagship Pioneering.
He received his undergraduate degree from Stanford University, a graduate degree from Stanford University and a doctorate degree from Massachusetts Institute of Technology.
Postes actifs de Jordi Mata-Fink
| Sociétés | Poste | Début |
|---|---|---|
Gate Bioscience, Inc.
Gate Bioscience, Inc. BiotechnologyHealth Technology Develops a small molecule modality to treat biology’s intractable diseases | Directeur Général | 01/01/2021 |
Anciens postes connus de Jordi Mata-Fink
| Sociétés | Poste | Fin |
|---|---|---|
Flagship Pioneering, Inc.
Flagship Pioneering, Inc. Investment ManagersFinance Flagship Pioneering invests in companies located across the globe. The firm targets companies operating in the fields of therapeutics, life science tools & diagnostics, bioenergy, and cleantech sectors. It provides financing for seed, early and later-stage capital requirements. The firm makes co-investments and also acts as a lead investor. | Analyste en capital-investissement | 01/09/2019 |
Cygnal Therapeutics, Inc.
Cygnal Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that discovers and develops drugs for treatments of cancer, immune-inflammatory disorders, fibrotic and degenerative diseases | Fondateur | - |
| RUBIUS THERAPEUTICS | Fondateur | - |
Formation de Jordi Mata-Fink
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Stanford University
Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Flagship Pioneering, Inc.
Flagship Pioneering, Inc. Investment ManagersFinance Flagship Pioneering invests in companies located across the globe. The firm targets companies operating in the fields of therapeutics, life science tools & diagnostics, bioenergy, and cleantech sectors. It provides financing for seed, early and later-stage capital requirements. The firm makes co-investments and also acts as a lead investor. | Finance |
Massachusetts Institute of Technology
Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Rubius Therapeutics, Inc.
Rubius Therapeutics, Inc. BiotechnologyHealth Technology Develops red cell therapeutics for cancer treatment | Health Technology |
Cygnal Therapeutics, Inc.
Cygnal Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that discovers and develops drugs for treatments of cancer, immune-inflammatory disorders, fibrotic and degenerative diseases | Health Technology |
Gate Bioscience, Inc.
Gate Bioscience, Inc. BiotechnologyHealth Technology Develops a small molecule modality to treat biology’s intractable diseases | Health Technology |
















